Form D · Biotechnology
ProLynx, Inc.
San Francisco, CA · CIK 0001802283
Offering snapshot reported Sep 10, 2020 · SEC filing
- Reported sold
- $55.2K Offering amount: $6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 28, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 10, 2020 | Initial | $55,244 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-375266
Source: Form D, filed Sep 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anurag Bagaria | Director |
| Marc Edwards | Director |
| Scott Karchmer | Executive |
| Michael Rabson | Director |
| William J. Rutter | Director |
| Daniel Santi | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
455 Mission Bay Boulevard South
San Francisco, CA, 94158
San Francisco, CA, 94158